|
- Press Release: NKTR-118 Shows Substantial Oral Bioavailability and Extended Half-Life In Phase 1 Clinical Data Presented at American Pain Society Meeting
- Poster #210: Results from a Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study Evaluating the Safety, Tolerability and
Pharmacokinetics of Oral Doses of NKTR-118 (PEG-Naloxol) May 7, 2008
- Press Release: Positive Results for NKTR-118 (oral PEG-naloxol) Presented At American Academy of Pain Management Meeting September 26, 2007
- Poster #27: Clinical Investigation of NKTR-118 as a Selective Oral Peripheral Opioid Antagonist Presented at the American Academy of Pain Management Meeting in Las Vegas, Nevada September 28, 2007
- Poster #28: NKTR-118 (oral PEG-naloxol), a PEGylated Derivative of Naloxone; Demonstration of Selective Peripheral Opioid Antagonism After Oral Administration in Preclinical Models Presented at the American Academy of Pain Management Meeting in Las Vegas, Nevada September 28, 2007
- Press Release: Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting September 10, 2007
- Poster #36: Evaluation of PEG-naloxol (NKTR-118) as an Oral Peripheral Opioid Antagonist in Healthy Male Subjects: A Double-Blind, Placebo-Controlled, Dose Escalation Crossover Study - Presented at the American College of Clinical Pharmacology 36th Annual Meeting in San Francisco, CA; September 10, 2007 Poster Session II
|
